American Academy of Dermatology Meeting

American Academy of Dermatology Meeting

April 05, 2019
2 min read

Efficacy, safety of psoriasis drug Taltz sustained over 4 years

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Taltz demonstrated high levels of efficacy and safety for the treatment of psoriasis over 4 years, according to research presented at the American Academy of Dermatology Annual Meeting.

“[Taltz (ixekizumab, Eli Lilly)] a high-affinity monoclonal antibody that selectively targets IL-17A, has shown sustained high efficacy response over 3 years with consistent safety profile in moderate-to-severe psoriasis patients,” Mark G. Lebwohl, MD, professor and system chair of dermatology at Mount Sinai Hospital, and colleagues wrote.

Lebwohl and colleagues conducted a study to determine if ixekizumab had sustained efficacy and safety over 4 years of treatment. They enrolled 1,346 patients with psoriasis. Participants were randomly assigned to one of four treatment groups during a 12-week induction period:

  • an initial dose of 160 mg of ixekizumab followed by 80 mg of ixekizumab every 2 weeks;
  • an initial dose of 160 mg of ixekizumab followed by 80 mg of ixekizumab every 4 weeks;
  • 50 mg of Enbrel (etanercept, Amgen) twice weekly; or
  • placebo.

At week 12, 1,274 patients entered the long-term extension phase of the study and received ixekizumab every 4 weeks and after week 60, dosing could be modified to every 2 weeks at the researchers’ discretion.

The researchers used several measurements to determine efficacy, including 75%, 90% or

100% improvement from baseline in the Psoriasis Area and Severity Index (PASI), a static Physician’s Global Assessment (sPGA) score of 0/1 or 0, complete resolution based on the Psoriasis Scalp Severity Index (PSSI = 0) and Palmoplantar Psoriasis Area and Severity Index (PPASI = 100).

They assessed treatment-emergent adverse events in patients who received at least one dose during the long-term extension period to evaluate safety.

About three-quarters of participants completed 4 years of the efficacy assessment.

Most patients taking ixekizumab every 2 or 4 weeks demonstrated improvement on all of the efficacy assessments (PASI 75: 82.9%; PASI 90: 68.9%; PASI 100: 49%; sPGA 0/1: 69.2%; sPGA 0: 50.3%; PSSI = 0: 73.4%; and PPASI = 100: 76.1%).

Of the 19.9% of patients who had their ixekizumab dose adjusted to every 2 weeks between week 60 and year 4, 59.8% showed 75% improvement in PASI before dose adjustment.

The overall safety profile of ixekizumab was consistent to year 4. Most treatment-emergent adverse events were mildly or moderately severe. The most common adverse event was infections (67.2%). There were eight (0.6%) deaths, according to the researchers.

“High efficacy response was demonstrated with ixekizumab treatment that sustained over 4 years in patients with moderate-to-severe plaque psoriasis,” Lebwohl and colleagues wrote. “The safety profile remained consistent with prior findings, with no or unexpected new safety concerns.” – by Alaina Tedesco



Lebwohl MG, et al. Abstract 10011. Presented at: American Academy of Dermatology Annual Meeting; March 1-5, 2019; Washington, D.C.

Disclosure: Lebwohl is a consultant for Allergan, Aqua, Arcutis, Boehringer Ingelheim, Leo Pharma, Menlo, Promius and Verrica.